HematologyNews.net

Hematology Xagena

In 2013 American Society of Hematology ( ASH ) Annual Meeting data on several compounds in development for the treatment of multiple myeloma were presented. Alternating vs sequential regimens I ...


The results of phase III study evaluating a JAK 1/2 inhibitor for the treatment of polycythemia vera were presented at the 50th Annual Meeting of the American Society of Clinical Oncology ( ASCO ). ...


Phosphatidylinositol-3-kinase delta ( PI3Kδ ) mediates B-cell receptor signaling and microenvironmental support signals that promote the growth and survival of malignant B lymphocytes. In a phase 1 ...


The monoclonal anti-CD20 antibody Rituximab ( MabThera, Rituxan ), combined with chemotherapeutic agents, has been shown to prolong overall survival in physically fit patients with previously untreate ...


Acute lymphoblastic leukemia ( ALL ) is a rare type of blood cancer which is mainly treated by intensive chemotherapy. If the disease is resistant to initial treatment or reoccurs ( relapse ) the cha ...


Patients with relapsed chronic lymphocytic leukemia ( CLL ) who have clinically significant coexisting medical conditions are less able to undergo standard chemotherapy. Effective therapies with accep ...


Immobilization of the lower leg is associated with venous thromboembolism ( VTE ). Low molecular weight Heparin ( LMWH ) is an anticoagulant treatment which might be used in adult patients with lower- ...


The combination of lenalidomide ( Revlimid ) and Rituximab ( Rituxan ) has shown synergistic activity in chronic lymphocytic leukemia ( CLL ) preclinical models. In a CLL Research Consortium phase I ...


Updated interim results of a phase 2 study ( Study 102 ) evaluating GS-9973, an investigational oral inhibitor of spleen tyrosine kinase ( Syk ), for the treatment of patients with relapsed chronic ly ...


Early results of a randomized phase III GITMO/FIL study comparing CHOP-R vs. R-HDS + ASCT as primary treatment in 134 FL pts, aged less than or equal to 60 yrs with aaIPI greater than 1/IIL score grea ...


The results from PANORAMA-1 ( PANobinostat ORAl in Multiple MyelomA ) trial were presented at ASCO meeting, showing a 37% improvement in progression-free survival ( PFS ) when using the investigationa ...


The FDA ( Food and Drug Administration ) has approved a Supplemental Biologic License Application ( sBLA ) for the use of Arzerra ( Ofatumumab ), a CD20-directed cytolytic monoclonal antibody, in comb ...


A group of researchers at the Institute for Research in Immunology and Cancer ( IRIC ) of Université de Montréal discovered a promising new approach to treating leukemia by disarming a gene that is re ...


The Food and Drug Administration ( FDA ) has expanded the approved use of Imbruvica ( Ibrutinib ) for chronic lymphocytic leukemia ( CLL ) patients who have received at least one previous therapy.Chro ...


VMP and Rd are two of the most efficient and widely accepted regimens in the treatment of elderly newly diagnosed multiple myeloma patients. In order to further improve the outcome of elderly patients ...